Lataa...
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma
Ipilimumab (IPI) 10 mg/kg with sargramostim (GM-CSF; GM) improved overall survival (OS) and safety of patients with advanced melanoma over IPI in a randomized phase II trial. The FDA-approved dose of IPI 3 mg/kg has not been assessed with GM (IPI-GM). Consecutive patients treated with IPI-GM at a si...
Tallennettuna:
| Julkaisussa: | Cancer Immunol Res |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4561189/ https://ncbi.nlm.nih.gov/pubmed/25943535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0066 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|